Janus kinase 1 JH2 pseudokinase domain (JAK1 JH2)

The Janus kinase 1 (JAK1) JH2 pseudokinase domain is a non-catalytic regulatory region located adjacent to the JH1 kinase domain within the JAK1 protein (UniProt, 2024). While it lacks the traditional phosphotransferase activity of a functional kinase, the JH2 domain plays a pivotal role as an allosteric switch that controls the activity of the JH1 catalytic domain (Nature Communications, 2014). In its resting state, the JH2 domain interacts with the JH1 domain to maintain an autoinhibited conformation, preventing premature signaling (Journal of Medicinal Chemistry, 2020). Upon cytokine binding to the associated receptor, this inhibition is relieved, allowing for downstream phosphorylation of STAT proteins (UniProt, 2024). Mutations in the JH2 domain can lead to constitutive activation of JAK1, contributing to inflammatory diseases and hematologic malignancies (Nature Communications, 2014). Consequently, the JH2 domain has become a significant therapeutic target for the development of allosteric inhibitors (Journal of Medicinal Chemistry, 2020). These inhibitors aim to stabilize the autoinhibited state, providing a mechanism to achieve high selectivity for JAK1 over other JAK family members, which is often difficult with traditional ATP-competitive inhibitors (Nimbus Therapeutics, 2023). This approach is expected to improve the safety profile of JAK inhibitors by reducing off-target effects associated with JAK2 or JAK3 inhibition (Nimbus Therapeutics, 2023).

Other names

Janus kinase 1 JH2 domainJAK1 pseudokinase domainJAK1-JH2Janus kinase 1 (JAK1) JH2 domain

Allosteric inhibition by binding to the JH2 domain and stabilizing the autoinhibitory interaction with the JH1 catalytic domain, thereby preventing kinase activation.